Who
Jason Drew Smith
General Counsel
Company insider
Files Form 4 as: General Counsel, UroGen Pharma.
In numbers
- Trades disclosed
- 88
- Buys
- 1
- Sells
- 13
- Bought
- $39K
- Sold
- $1.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Sep 2020
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $65K1,519 at $42.54 | filing |
| 8 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $65K1,519 at $42.54 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —3,334 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,334 at $0.00 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,334 at $0.00 | filing |
| 7 Sep 2026filed 9 Sep 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —3,334 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $52K2,654 at $19.69 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $32K1,608 at $19.69 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $63K3,217 at $19.69 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $52K2,654 at $19.69 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $32K1,608 at $19.69 | filing |
| 3 Feb 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Sold | $63K3,217 at $19.69 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —5,500 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,609 at $0.00 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —3,333 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,500 at $0.00 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,333 at $0.00 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,667 at $0.00 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,609 at $0.00 | filing |
| 31 Jan 2026filed 11 Feb 2026 | URGN UroGen PharmaBiotechnology | SEC FORM 4 Code M | —6,667 | filing |
News
UroGen Pharma Announces FDA Acceptance Of UGN-103 NDA For ReviewURGN · rttnews.com · 19 Oct 2026Analyzing Urogen Pharma (NASDAQ:URGN) and Incannex Healthcare (NASDAQ:IXHL)URGN · themarketsdaily.com · 15 Oct 2026Reviewing Cronos Group (NASDAQ:CRON) and Urogen Pharma (NASDAQ:URGN)URGN · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Jason Drew Smith; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.